Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Semagludtide · 1 trial · 1 indication
Score on scale (0 to 18) Measures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer's disease: * Cognitive domains: memory, orientation, and judgement and problem solving * Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents "none" to "severe" impairment for each of the six domains. The CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.
| Arm | Type | Description |
|---|---|---|
| Oral Semaglutide | EXPERIMENTAL | Participants are given oral semaglutide once daily |
| Placebo (semagludtide) | PLACEBO_COMPARATOR | Participants are given oral placebo once daily |
| Name | Type | Description |
|---|---|---|
| Semagludtide | DRUG | Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks |
| Placebo (semaglutide) | DRUG | Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks |
Inclusion Criteria: * Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent. * MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type according to the NIA-AA (National Institute of Aging-Alzheimer's Association) 2018 criteria. * CDR (Clinical De...
Semaglutide is being investigated as a treatment for early Alzheimer's disease. It is a small molecule developed by Novo Nordisk A/S. The drug has completed a Phase 3 clinical trial in this indication, though it remains investigational and is not yet approved for Alzheimer's disease.
Semaglutide is a small molecule being studied for early Alzheimer's disease. Its molecular target has not been specified in the available information, so its mechanism of action in this context is not detailed here.
Semaglutide is developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical research on this drug for early Alzheimer's disease.
Semaglutide is in Phase 3 clinical development for early Alzheimer's disease. A Phase 3 trial has been completed, but the drug is still investigational and has not been approved by regulatory authorities for this condition.
Semaglutide has one completed Phase 3 trial, NCT04777396, titled 'A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)'. This randomized, double-blind, placebo-controlled study enrolled 1,840 participants across multiple countries.
Semaglutide is the same drug name used in studies for early Alzheimer's disease. The available information does not specify whether this is the identical compound used for other indications, so no distinction is made here.